Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach
暂无分享,去创建一个
Kai-Cheng Hsu | Jui-Hua Hsieh | Jinn-Moon Yang | Wei-Jan Huang | Chang-Yi Liu | Tony Eight Lin | Tzu-Ying Sung | Hui-Ju Tseng
[1] Kai-Cheng Hsu,et al. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis , 2011, BMC Bioinformatics.
[2] Hongwei Song,et al. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[3] P. Marks,et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Horinouchi,et al. In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.
[5] R. Johnstone,et al. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.
[6] James Bradner,et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.
[7] B. Gryder,et al. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. , 2012, Future medicinal chemistry.
[8] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[9] F. Dequiedt,et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.
[10] C. Mercurio,et al. Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next , 2014, ChemMedChem.
[11] V. Kiermer,et al. The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[12] Torsten Schwede,et al. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..
[13] James E. Bradner,et al. Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.
[14] Chun Li Zhang,et al. Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.
[15] V. Adam,et al. Histone deacetylase inhibitors in cancer therapy. A review. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[16] Alessandra Nurisso,et al. How the flexibility of human histone deacetylases influences ligand binding: an overview. , 2015, Drug discovery today.
[17] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[18] I. Torres-Aleman,et al. The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.
[19] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[20] 芳原 輝之. Altered gene expression of histone deacetylases in mood disorder patients , 2012 .
[21] D. Menick,et al. A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease. , 2016, American journal of physiology. Heart and circulatory physiology.
[22] L. Thompson,et al. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.
[23] Takayoshi Suzuki,et al. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. , 2005, Bioorganic & medicinal chemistry.
[24] Manel Esteller,et al. The role of histone deacetylases (HDACs) in human cancer , 2007, Molecular oncology.
[25] David L. Wheeler,et al. GenBank , 2015, Nucleic Acids Res..
[26] R. A. Reid,et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. , 2013, Nature chemical biology.
[27] T. Yao,et al. Intracellular Trafficking of Histone Deacetylase 4 Regulates Neuronal Cell Death , 2005, The Journal of Neuroscience.
[28] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[29] G. Mulder,et al. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. , 1983, Environmental health perspectives.
[30] Takeshi Inoue,et al. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. , 2005, Biochemical pharmacology.
[31] J. Ryan,et al. Epigenetics and depressive disorders: a review of current progress and future directions. , 2015, International journal of epidemiology.
[32] Marco Biasini,et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..
[33] S. Minucci,et al. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? , 2011, Expert opinion on drug discovery.
[34] C. Brancolini,et al. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis , 2011, Journal of cellular and molecular medicine.
[35] John P. Overington,et al. PDBLIG: classification of small molecular protein binding in the Protein Data Bank. , 2004, Journal of medicinal chemistry.
[36] T. Beckers,et al. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening. , 2008, Analytical biochemistry.
[37] A. Strongin,et al. Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase. , 2011, Assay and drug development technologies.
[38] Wei-Guo Zhu,et al. Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications , 2014, International journal of biological sciences.
[39] Seth M. Cohen,et al. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity , 2006, JBIC Journal of Biological Inorganic Chemistry.
[40] Eric J. Nestler,et al. Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.
[41] Minoru Yoshida,et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.
[42] M. Bottomley,et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[43] K. Parang,et al. Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase. , 2006, Journal of medicinal chemistry.
[44] S. Elgin,et al. Heterochromatin and gene regulation in Drosophila. , 1996, Current opinion in genetics & development.
[45] A. Monks,et al. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts , 2009, Anti-cancer drugs.
[46] Geoffrey J. Barton,et al. Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..
[47] P. L. Puri,et al. Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases , 2011, Molecular medicine.
[48] Raymond Scott Turner,et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease , 2013, Experimental Neurology.
[49] E. Olson,et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.
[50] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[51] O. Wiest,et al. Computational exploration of zinc binding groups for HDAC inhibition. , 2013, The Journal of organic chemistry.
[52] R. Bürli,et al. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. , 2013, Journal of medicinal chemistry.
[53] U. Koch,et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.
[54] P. Atadja. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.
[55] W-S Xu,et al. Histone deacetylase inhibitors: Potential in cancer therapy , 2009, Journal of cellular biochemistry.
[56] Thomas Lengauer,et al. Computational methods for biomolecular docking. , 1996, Current opinion in structural biology.
[57] C. Fierke,et al. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators. , 2016, ACS chemical biology.
[58] R. Johnstone,et al. New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.
[59] Naoya Nagata,et al. Metal-ligand interactions: an analysis of zinc binding groups using the Protein Data Bank. , 2012, European journal of medicinal chemistry.
[60] M. Monga,et al. Developmental Therapeutics Program at the NCI: molecular target and drug discovery process , 2002, Leukemia.
[61] John M. Shelton,et al. Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis , 2004, Cell.
[62] Johan Auwerx,et al. Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.
[63] K. Glaser,et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.
[64] E. Olson,et al. Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development , 2004, Molecular and Cellular Biology.
[65] Y. Peterson,et al. Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. , 2016, Journal of medicinal chemistry.
[66] Eric Verdin,et al. Histone Deacetylase 7 Functions as a Key Regulator of Genes Involved in both Positive and Negative Selection of Thymocytes , 2007, Molecular and Cellular Biology.
[67] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[68] D. Wegener,et al. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. , 2003, Chemistry & biology.
[69] O. Wiest,et al. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. , 2009, Current topics in medicinal chemistry.
[70] Guanghua Xiao,et al. Histone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli , 2007, Neuron.
[71] Hwanho Choi,et al. MetLigDB: a web-based database for the identification of chemical groups to design metalloprotein inhibitors , 2011 .
[72] M. Binaschi,et al. Histone Deacetylase Inhibitors: From Bench to Clinic , 2008 .